Welcome to the calm before the Covid-19 storm.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?